转移性肾细胞癌的靶向治疗。
Targeted therapy in metastatic renal carcinoma.
机构信息
Chief of Urology, Denver Health Medical Center, 777 Bannock Street, Denver, CO 80204, United States.
Chief of Urology, Denver Health Medical Center, 777 Bannock Street, Denver, CO 80204, United States.
出版信息
Cancer Lett. 2014 Feb 28;343(2):156-60. doi: 10.1016/j.canlet.2013.09.038. Epub 2013 Nov 13.
BACKGROUND
Advanced renal cell carcinoma is one of the most treatment-resistant malignancies to conventional cytotoxic chemotherapy. The development of new targeted therapy was result of understanding biological pathways underlying renal cell carcinoma. Our objective is to provide an overview of current therapies in metastatic renal cell carcinoma.
METHODS
MEDLINE/PUBMED was queried in December 2012 to identify abstracts, original and review articles. The research was conducted using the following words: "metastatic renal cell carcinoma" and "target therapy". Phase II and Phase III clinical trials were included followed FDA approval. Total of 40 studies were eligible for review.
CONCLUSION
The result of this review shows benefit of these target drugs in tumor burden, increase progression-free and overall survival and improvement the quality of life compared with previous toxic immunotherapy, although complete response remains rare.
背景
晚期肾细胞癌是对传统细胞毒化疗最具耐药性的恶性肿瘤之一。新的靶向治疗的发展是对肾细胞癌潜在生物学途径的理解的结果。我们的目的是提供转移性肾细胞癌的当前治疗方法概述。
方法
2012 年 12 月，我们在 MEDLINE/PUBMED 上查询了摘要、原始和综述文章。使用以下关键词进行了研究：“转移性肾细胞癌”和“靶向治疗”。包括 FDA 批准的 II 期和 III 期临床试验。共有 40 项研究符合审查标准。
结论
这项综述的结果表明，与以前的毒性免疫疗法相比，这些靶向药物在肿瘤负荷、无进展生存期和总生存期的改善以及生活质量的提高方面具有优势，尽管完全缓解仍然很少见。
Zotero 插件